AzurRx launches OPTION 2 cystic fibrosis trial in Europe
MS1819 will be given in enteric capsules for gastric protection and optimal delivery of enzyme to the duodenum. Credit: Mahmoud Ahmed from Pixabay.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more
